Royal London Asset Management
BIO icon

Royal London Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Royal London Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,163
Closed -$283K – 722
2025
Q1 		$283K Buy
+1,163
New +$350K ﹤0.01% 719
2024
Q3 		– Sell
-6,895
Closed -$1.88M – 638
2024
Q2 		$1.88M Hold
6,895
– – ﹤0.01% 618
2024
Q1 		$2.38M Sell
6,895
-242
-3% -$79.6K 0.01% 614
2023
Q4 		$2.3M Sell
7,137
-1,046
-13% -$328K 0.01% 617
2023
Q3 		$2.93M Buy
8,183
+616
+8% +$238K 0.01% 603
2023
Q2 		$2.87M Hold
7,567
– – 0.01% 596
2023
Q1 		$3.62M Buy
7,567
+770
+11% +$360K 0.01% 540
2022
Q4 		$2.86M Buy
6,797
+1,048
+18% +$423K 0.01% 572
2022
Q3 		$2.4M Sell
5,749
-204
-3% -$102K 0.01% 576
2022
Q2 		$2.94M Sell
5,953
-245
-4% -$128K 0.01% 559
2022
Q1 		$3.49M Buy
6,198
+271
+5% +$163K 0.01% 575
2021
Q4 		$4.48M Hold
5,927
– – 0.02% 523
2021
Q3 		$4.42M Hold
5,927
– – 0.02% 522
2021
Q2 		$3.82M Buy
+5,927
New +$3.61M 0.02% 568
2021
Q1 		– Sell
-5,619
Closed -$3.28M – 665
2020
Q4 		$3.28M Buy
5,619
+602
+12% +$343K 0.02% 535
2020
Q3 		$2.59M Buy
+5,017
New +$2.54M 0.02% 530
2019
Q1 		– Sell
-11,645
Closed -$2.7M – 657
2018
Q4 		$2.7M Buy
11,645
+417
+4% +$112K 0.02% 544
2018
Q3 		$3.52M Sell
11,228
-482
-4% -$150K 0.04% 414
2018
Q2 		$3.38M Buy
+11,710
New +$3.23M 0.03% 471
2016
Q2 		$2.72M Buy
+19,045
New +$2.72M 0.04% 401
2016
Q1 		– Sell
-15,430
Closed -$2.15M – 523
2015
Q4 		$2.15M Sell
15,430
-93
-0.6% -$12.9K 0.03% 464
2015
Q3 		$2.08M Buy
+15,523
New +$2.23M 0.03% 468
2014
Q3 		– Sell
-16,400
Closed -$1.99M – 557
2014
Q2 		$1.99M Sell
16,400
-400
-2% -$48.8K 0.05% 414
2014
Q1 		$2.07M Buy
+16,800
New +$2.15M 0.05% 403

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Royal London Asset Management's BIO Position: Q2 2025 in Review

Royal London Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 1,163 shares — an estimated $283K sold.

Royal London Asset Management first reported a position in BIO in Q1 2014 and held it in 24 quarters. The position peaked at $4.48M in Q4 2021. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

  • Royal London Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
  • Royal London Asset Management sold 1,163 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $283K.
  • Royal London Asset Management first reported a position in Bio-Rad Laboratories Class A in Q1 2014 and held it in 24 quarters.
  • Royal London Asset Management's Bio-Rad Laboratories Class A position peaked at $4.48M in Q4 2021.
  • 384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Royal London Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.